castration — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T6889	MI-136		Apoptosis , Epigenetic Reader Domain , Androgen Receptor
	MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced.		Apoptosis , Epigenetic Reader Domain , Androgen Receptor
T8217	Enzalutamide carboxylic acid		Androgen Receptor , Drug Metabolite
	Enzalutamide carboxylic acid is an antagonist of androgen receptor (AR) .		Androgen Receptor , Drug Metabolite
T21740	RD162		Androgen Receptor
	RD162 is a non-steroidal antiandrogen (NSAA) specifically binding to the androgen receptor (AR).		Androgen Receptor
T9246	JNJ-63576253		Androgen Receptor
	JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).		Androgen Receptor
T22263	Bavdegalutamide	ARV-110	Androgen Receptor
	Bavdegalutamide (ARV-110) is a PROTAC degrader of androgen receptor (AR). Bavdegalutamide can be used in studies about prostate cancer. Bavdegalutamide shows oral activity and selectivity and facilitates the ubiquitinati...		Androgen Receptor
T36841	IPI-9119		Fatty Acid Synthase
	IPI-9119 is an orally active, selective and irreversible FASN inhibitor (IC50 = 0.3 nM).		Fatty Acid Synthase
T0380	Bicalutamide	ICI-176334	Androgen Receptor , Autophagy
	Bicalutamide (ICI-176334), a synthetic, nonsteroidal antiandrogen, competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens.		Androgen Receptor , Autophagy
T8933	JNJ-63576253 free base	TRC253,JNJ-63576253	Androgen Receptor
	JNJ-63576253 free base (TRC253) is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the re...		Androgen Receptor
T2895	Lupeol	Fagarasterol,Monogynol B,Clerodol,(3β,13ξ)-Lup-20(29)-en-3-ol,Farganasterol	Apoptosis , Androgen Receptor , Akt
	Lupeol (Monogynol B) is a novel androgen receptor inhibitor with anti-inflammatory and antioxidant activity.		Apoptosis , Androgen Receptor , Akt
TQ0214	Dimethylcurcumin	ASC-J9,GO-Y025	Androgen Receptor
	Dimethylcurcumin (ASC-J9) (ASC-J9) is an androgen receptor degradation enhancer. It effectively suppresses castration-resistant prostate cancer cell proliferation and invasion.		Androgen Receptor
T0272	Nilutamide	RU23908	Androgen Receptor
	Nilutamide (RU23908), an antineoplastic hormonal agent, is mainly used in the treatment of prostate Y. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors, but not for estrogen, progesto...		Androgen Receptor
T6215	Abiraterone Acetate	Zytiga,CB7630	P450
	Abiraterone Acetate (CB7630) is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.		P450
T2543	Cabazitaxel	XRP6258,RPR-116258A,TXD 258,taxoid XRP6258	Microtubule Associated , Autophagy
	Cabazitaxel (taxoid XRP6258) is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel.		Microtubule Associated , Autophagy
T8497	SX-682		CXCR
	SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.		CXCR
T13363	Y06137		Epigenetic Reader Domain , PKC
	Y06137 is an effective and selective BET inhibitor with a Kd of 81 nM for BRD4(1) bromodomain. Y06137 can be used for research on the treatment of castration-resistant prostate cancer.		Epigenetic Reader Domain , PKC
T13671	(S,R,S)-AHPC-Me hydrochloride	VHL ligand 2 hydrochloride,E3 ligase Ligand 1	Others , Ligand for E3 Ligase
	(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is a chemical compound utilized in the synthesis of ARV-771, an exceptionally potent BET protein degrader. This compound selectively degrades BET protein in cell...		Others , Ligand for E3 Ligase
T76758	Rilotumumab	AMG 102	c-Met/HGFR
	Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (...		c-Met/HGFR
T76743	Emibetuzumab	LY2875358	c-Met/HGFR
	Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study adv...		c-Met/HGFR
T7752	(S,R,S)-AHPC-Me	VHL ligand 2,E3 ligase Ligand 1A	Ligand for E3 Ligase
	(S,R,S)-AHPC-Me (E3 ligase Ligand 1A) (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein[1]. (S,R,S)-AHPC-Me can be used to synthesize ARV-771. ARV-771 is a...		Ligand for E3 Ligase
T26831	BKM1644	BKM 1644,BKM-1644
	BKM1644 is an effective inhibition of the proliferation of metastatic, castration-resistant PCa (mCRPC) cells.